Taysha Gene Therapies, Inc. TSHA
We take great care to ensure that the data presented and summarized in this overview for Taysha Gene Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TSHA
View all-
Avoro Capital Advisors LLC New York, NY18.7MShares$57.6 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$57.5 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$27.8 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$18.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.17MShares$16 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY4MShares$12.4 Million0.15% of portfolio
-
Tybourne Capital Management (Hk) LTD Hong Kong, K33.7MShares$11.4 Million2.38% of portfolio
-
Artal Group S.A. Luxembourg, N43.69MShares$11.4 Million0.57% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA3.33MShares$10.3 Million7.82% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.14MShares$9.69 Million0.0% of portfolio
Latest Institutional Activity in TSHA
Top Purchases
Top Sells
About TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Insider Transactions at TSHA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2024
|
Kamran Alam CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,288
-0.15%
|
$1,288
$1.51 P/Share
|
|
Jan 02
2024
|
Sean P. Nolan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,184,688
+49.98%
|
-
|
|
Jan 02
2024
|
Sukumar Nagendran President and Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
863,617
+49.03%
|
-
|
|
Jan 02
2024
|
Kamran Alam CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
590,413
+41.21%
|
-
|
|
Nov 17
2023
|
Paul B Manning > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.6%
|
$100,000
$1.63 P/Share
|
|
Aug 24
2023
|
Kamran Alam CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
33,000
-11.34%
|
$66,000
$2.33 P/Share
|
|
Aug 16
2023
|
Paul B Manning > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,466,667
+50.0%
|
$0
$0.9 P/Share
|
|
Aug 16
2023
|
Phillip B. Donenberg Director |
BUY
Open market or private purchase
|
Direct |
111,111
+49.33%
|
$0
$0.9 P/Share
|
|
Aug 16
2023
|
Sean P. Nolan Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
444,444
+22.45%
|
$0
$0.9 P/Share
|
|
Aug 16
2023
|
John A Stalfort Iii Director |
BUY
Bona fide gift
|
Direct |
50,000
+4.55%
|
-
|
|
Aug 16
2023
|
John A Stalfort Iii Director |
BUY
Open market or private purchase
|
Direct |
388,889
+28.01%
|
$0
$0.9 P/Share
|
|
Aug 16
2023
|
John A Stalfort Iii Director |
BUY
Open market or private purchase
|
Indirect |
388,889
+30.54%
|
$0
$0.9 P/Share
|
|
Jul 13
2023
|
R.A. Session Ii |
SELL
Open market or private sale
|
Direct |
5,344
-0.06%
|
$0
$0.7 P/Share
|
|
Jul 12
2023
|
R.A. Session Ii |
SELL
Open market or private sale
|
Direct |
80,528
-0.9%
|
$0
$0.71 P/Share
|
|
Jun 23
2023
|
R.A. Session Ii |
SELL
Open market or private sale
|
Direct |
18,100
-0.2%
|
$0
$0.7 P/Share
|
|
Jun 22
2023
|
R.A. Session Ii |
SELL
Open market or private sale
|
Direct |
10,508
-0.12%
|
$0
$0.7 P/Share
|
|
Jun 21
2023
|
R.A. Session Ii |
SELL
Open market or private sale
|
Direct |
138,962
-1.52%
|
$0
$0.7 P/Share
|
|
Jun 20
2023
|
R.A. Session Ii |
SELL
Open market or private sale
|
Direct |
295,653
-3.14%
|
$0
$0.71 P/Share
|
|
May 31
2023
|
Kamran Alam CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,230
+2.1%
|
-
|
|
May 16
2023
|
Sukumar Nagendran President and Head of R&D |
BUY
Open market or private purchase
|
Direct |
5,000
+12.75%
|
$0
$0.68 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 17.9M shares |
|---|---|
| Bona fide gift | 50K shares |
| Grant, award, or other acquisition | 2.64M shares |
| Payment of exercise price or tax liability | 1.29K shares |
|---|---|
| Open market or private sale | 582K shares |